SGO Numbers: Some Winners, Many Disappointments Await
Lots of gaudy headline numbers coming out of SGO this year; do they stack up under scrutiny? My take – some winners likely and many tears before bedtime for others. Which ones fall in the latter category? Find out: https://t.co/aLkUwZ0FrJ https://t.co/DzIVks0nxg
REPL RP1 Melanoma Trial Flawed; New CRL
I've never covered the REPL RP1 data in melanoma, mainly due to dislike of the trial design w/ its lack of a monotherapy arm. Sometimes you can see where things are likely headed and kicking a dog when it's down...
New Cytotoxic Targets Unveiled at AACR26
Time to head off the beaten track at #AACR26 with our latest preview exploring novel targets and cytotoxics. The long climb up the hill may be worth it for some of them: https://t.co/l9tkdWvpuF https://t.co/M5B3RTW1wf
Myeloma Survival Breakthrough: Two Decades After Dalton’s Wish
I remember interviewing Bill Dalton in 2005 about new developments in myeloma and how he wished for new regimens to take OS out beyond 3-4 yrs. Two decades on we've hit jackpot...
New Early-Stage Cancer Drugs Emerge at AACR26
A look at some promising early stage drug developments coming down the pike at #AACR26. A few of these concepts were not on the radar a couple of years ago: https://t.co/w6oD4CEckq https://t.co/kfR1AXG41K
Setidegrasib’s KRAS Degradation Still Unproven in Cancer
Elegant in theory, unproven in practice: setidegrasib and the case (or not) for KRAS degradation in NSCLC and pancreatic cancer: https://t.co/NuaOJ2amgn https://t.co/i9FpK4W19W
CytomX CRC Data Demand Double‑Take, Not Clear Verdict
Some clinical updates tell you exactly what they are. Others ask to be read twice. CytomX’s latest CRC data belong firmly in the second category. Is the die cast? https://t.co/dfdPxx4zXs https://t.co/y9QAoahMut
Emerging KRAS Combo Therapies Show Promising Progress
The KRAS niche has been a deluge of new selective and pan/multi inhibitors. Now there are combos to watch out for – we may be making progress. Here are insights on 7 of them: https://t.co/F9HmM8A4ud https://t.co/IqWw6n2m3k
Bladder Cancer Landscape Shifts, Opening New Strategic Opportunities
When cancer niches are rapidly changing they create both a vacuum of indecision and fresh opportunities for smart players. Here we explore bladder cancer and look at where the field is headed... https://t.co/cf93Qb8dhe https://t.co/fx5V1MVwYN
Comparing Lorigerlimab, Volrustomig, Cadonilimab: Design Lessons
An intriguing tale of three cities. How do the PD1xCTLA4 bispecific agents lorigerlimab, volrustomig, and cadonilimab stack up when it comes to design and performance? Some useful and pointed lessons here for biotech execs: https://t.co/xaSW15Fvdl https://t.co/dhXbiI3N6v
Emerging Protein Degradation Trends and CAR‑T Synergies
What gets missed in the hurly burly of a conference with many highlight reels? Here we explore emerging trends to watch out for when it comes to protein degradation/glues, & combination opportunities w/ CAR-T cells. Time for some...
Key Differences Between Anti‑cel and Cilta‑cel Explain GILD Deal
By chance I was writing about anito-cel vs. cilta-cel on Friday, not knowing $GILD acquisition was coming down the pike. There are some crucial differences between the two products to take note of, which may explain why they were...
European ADC Agents with Novel Targets Gain Momentum
With all the attention on China for TOPO-I ADCs of late, how about the potential for European agents, especially ones involving novel targets? Our latest expert interview drops with some hard hitting and candid opinions from a battle hardened...
Zanidatamab Gastric Cancer Data Faces Seven Bearish Concerns
It's good to see new trial readouts at #GI26, although there are 7 reasons to be bearish about the zanidatamab data in gastric cancer: https://t.co/g2MbrPI7Iu https://t.co/tBY2yJ6YMe
Zanidatamab Plus Tislelizumab Raises Diarrhea Risk
#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx
